Clinical Trials
Daewoong Pharmaceutical’s Bersiporocin Clears Third IDMC Safety Review, Global Phase 2 IPF Trial to Continue
Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study 94 patients enrolled out of 102 planned across K...
October 28, 2025 | News
OncoC4 and BioNTech’s Gotistobart Receives Breakthrough Therapy Designation in China for Squamous Non-Small Cell Lung Cancer
Designation granted for gotistobart (BNT316/ONC392) for the treatment of patients with squamous non-small cell lung cancer (sqNSCLC), an aggressive subtype...
October 28, 2025 | News
Alphamab Oncology Doses First Patient in Global First PD-L1/αvβ6 Bispecific ADC Clinical Trial
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I...
October 27, 2025 | News
EMA Grants Orphan Drug Designation to Ribo’s RBD1016 for Treatment of Hepatitis D Virus Infection
Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), announced that the European Medicines Agency (EMA) has granted O...
October 27, 2025 | News
Venus Medtech Completes Patient Enrollment in Cardiovalve TARGET Study for Tricuspid Valve Replacement
Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") announced the successful completion of patient enrollmen...
October 27, 2025 | News
METiS TechBio’s AI-Designed MTS-004 Meets Phase III Success in China, Targeting Pseudobulbar Affect
MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) METiS TechBio, a global leader in AI-driven nanodelivery and formulatio...
October 24, 2025 | News
Takeda and Innovent Biologics Announce Global Collaboration for Two Late-Stage Oncology Programs Valued at Over US$1.2 Billion
Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to Li...
October 23, 2025 | News
AdvanCell’s Lead-212 Radioligand Therapy Shows Strong Safety and Efficacy in Phase 1b Trial for Metastatic Prostate Cancer
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastat...
October 22, 2025 | News
Thermo Fisher’s PPD Business Launches Carbon Calculator to Drive Sustainable Clinical Research
New tool helps sponsors measure, manage and minimize the environmental impact of research The PPD™ clinical research business of Thermo Fisher Scien...
October 22, 2025 | News
Sanofi’s Efluelda (Fluzone High-Dose) Cuts Influenza Hospitalisations by 31.9% in Adults Aged 65+
Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by a...
October 21, 2025 | News
Sichuan Kelun-Biotech’s Trastuzumab Botidotin Approved in China for HER2-Positive Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor recep...
October 20, 2025 | News
Ascletis Completes U.S. Phase IIa Enrollment for Once-Monthly ASC30 GLP-1 Depot Therapy in Obesity
The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) d...
October 20, 2025 | News
Aurion Biotech Data Supports Advancing High-Dose AURN001 Regenerative Cell Therapy to Phase 3 Trial in 2026
Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1...
October 20, 2025 | News
Daiichi Sankyo and AstraZeneca’s DATROWAY Combination Delivers 68.2% Response and 95.5% Disease Control in First-Line Metastatic Urothelial Cancer
A confirmed objective response rate of 68.2% and a disease control rate of 95.5% was observed with Daiichi Sankyo and AstraZeneca’s DATROWAY in c...
October 20, 2025 | News
Most Read
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
